Changes between Version 7 and Version 8 of Research/DesignStudy/SteeringGroup/2020-07-03


Ignore:
Timestamp:
Jul 3, 2020, 3:33:44 PM (4 years ago)
Author:
longkr
Comment:

--

Legend:

Unmodified
Added
Removed
Modified
  • Research/DesignStudy/SteeringGroup/2020-07-03

    v7 v8  
    33 //**3^rd^ July  2020 10:00 GMT**//
    44 
    5 == Connection details ==
     5**Present:** KL, KK, SG, CB, CH, CW, JPa, JPar, JC, PA, RMcL, AP, TKW
    66
    7 Please join ZOOM meeting at: **https://cern.zoom.us/j/96325392842?pwd=cnNGeWhGeHlsb09PY0tVTEYwWUdlUT09**
     7== Summary of actions ==
     8 * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     9 * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     10 * **KL/KK**: to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     11 * **KL**: Ensure one representative per group at the next LhARA SG meeting.
     12 * **KL**: Raise NIHR engagement with K.Gleeson.
     13 * **KL**: Seek PPI representative for SG.
     14 * **KK, JPar, CW, KL**: Make relevant contact with local PPI groups as described in item 4.
     15 * **KL&JPar**: Write to CTRAD w/s 4 chair (KK) to ask how we might work together to raise awarenents of our programme among the patient and clinician communitites.
     16 * **KK, JPar, CW, KL, SG**: Make relevant contact with local clinician groups as described in item 4.
     17 * **KL**: Review proposed w/p structure and skills matrix taking into account comments under item 4.
     18 * **KL/RMcL**: Liaise to generate small group to coordinate development of instrumentation aspects of the programme.
     19
     20== Notes ==
     21
     221. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:]
     23 * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme.
     24  * **Ongoing.**  Need to step up the priority of this activity as we prepare the EPSRC proposal.
     25 * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF.
     26  * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast.  Agreed, morph action to include all.
     27 * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020.
     28  * **Stands.** Agenda item.
     29 * **KL** Send out diary invitation straight away to get it into the diary.
     30  * **Done.**
     31
     322. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\
     33 See slides which contain a brief status report as well as the provocation of the discussion for agenda item 4.
     34 
     353. Discussion of SG composition: KL/All
     36 - We agreed to re-set the SG composition to include one representative per group, the work-package managers (once they are defined), and co-opted members as required.  **KL** will work towards proper representation at the next SG meeting.
     37 - JPar noted that it would be important to make sure that groups were represented in the meeting and insitute Directors may need to be encouraged to delegate appropriately.
     38 
     394. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All
     40 * Dealing with feedback from our 2019 submission: \\
     41   "//Engagement with patients, clinicians and industry could have been strengthened//"
     42  - Patient engagement:
     43   - Actions taken to date include engagement with the PPI group at CXH in London.  These contacts will be taken forward.
     44   - We **agreed**:
     45    - Make local contacts by partner:
     46     - **KK**: Manchester
     47     - **JPar**: Liverpool
     48     - **CW**: Glasgow -- JPar will help with introduction to Anthony Chalmers, ex chair of CTRAD
     49     - **KL**: Will contact K.Prise in Belfast to see whether/how contact to PPI can be made.
     50    - With local contacts made we'll try and coordinate broader activity, Perhaps K.Gleeson (CXH) may take a role here.
     51    - CTRAD: important to bring Workstreams 1 and 4 into the patient- and clinician-engagement activities.  **KL&JPar** will write to KK in her capacity as W/s4 chair to ask for help in this regard.
     52    - NIHR: Various local groups, including one in London with which K.Gleeson is in contact.  Seek to exploit NIHR.  **KL** will raise possibility with K.Gleeson.
     53   - General comment from SG: need to ask what is important to patients.  We discussed co-opting a PPI member to our SG.  **KL** agreed to ask the author of the Lay Summaries of the pre-CDR and the publication if he would be willing to play this role.
     54  - Clinician engagement:
     55   - Within Imperial Trust and College contacts with clinicians and medical physicists good and being strengthened.  We discussed the need to develop links with clinicians at the various partner institutes.  We **agreed**:
     56    - **SG**: Birmingham
     57    - **JPar**: Liverpool
     58    - **KK**: Manchester (perhaps in collaboration with N. Burnett)
     59    - **CW**: Glasgow -- JPar will help with introduction to Anthony Chalmers, ex chair of CTRAD
     60    - **KL**: Contact K. Prise and M. Borghesi re clinician contact in Belfast.
     61  - As in the case of patient engagement we **agreed** to contact CTRAD to seek support in reaching out.  **KL/JPar** will write to the KK to seek support in this endeavour.
     62  - Industrial engagement:
     63   - Some contacts made at time of preparation of last meeting and need to push forward to enhance the industrial engagement going forward.  After discussing how to proceed we **agreed**:
     64    - **KL**: Will write to J.Clarke to ask for support to reach out to relevant industry.
     65    - **PA**: Will make contact with MTC to see how to make contact with relevant industry. **PA/KL** will cooperate in drafting a letter.
     66   - Possible engagement: Teledyne-E2V; Oxford Instruments, FMD-Oxford, STFC engagement team.
     67   - We noted the possibility that we should get a person to coordinate our industrial engagement.
     68 * Slides to initiate discussion of (done under 2 above):
     69  - Scope: we agreed to target first radiobiology exposures on LhARA within the 5-year scope of the bid.
     70  - We discussed the w/p structure.  KK pointed out that it needed to map explicitly to the EPSRC priority deliverables.  **KL** will take a second look at the proposed w/p structure and propose a revision.
     71  - Stakeholders from whom we should be seeking support; --All--
     72   - TKW proposed to make a diagram showing expertise required vs expertise available.  **KL** will coordinate the creation of such a diagram.  This diagram will also be valuable in negotiations with partners.
     73 
     745. Follow-up discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all
     75 - KL reported that R.McLauchlan (CXH) had agreed to take an overview/coordinating role in this area.  RMcL explained the vision to bring people together to understand what the opportunities are and how to bring the activity together into a coherent programme.
     76 - PA pointed out the need to take a staged approach with an initial focus on making sure the beam delivered is appropriate.
     77 - JPar pointed out that Liverpool has a Centre for Pre-Clinical Imaging.
     78 - We agreed to work towards a small sub-group to guide the development of the meeting and subsequently guide the development of the activity.  **KL/RMcL** will liaise to bring this about.
     79
     806. DONMs \\
     81 * 04 Sep 2020; 10:00 BST
     82
     837. AoB \\
     84 - None.
     85 
     86----
    887
    988== Agenda ==